These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28932756)

  • 1. Non-clinical Safety and Efficacy of an AAV2/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI.
    Ferla R; Alliegro M; Marteau JB; Dell'Anno M; Nusco E; Pouillot S; Galimberti S; Valsecchi MG; Zuliani V; Auricchio A
    Mol Ther Methods Clin Dev; 2017 Sep; 6():143-158. PubMed ID: 28932756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8.
    Ferla R; O'Malley T; Calcedo R; O'Donnell P; Wang P; Cotugno G; Claudiani P; Wilson JM; Haskins M; Auricchio A
    Hum Gene Ther; 2013 Feb; 24(2):163-9. PubMed ID: 23194248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer.
    Cotugno G; Annunziata P; Tessitore A; O'Malley T; Capalbo A; Faella A; Bartolomeo R; O'Donnell P; Wang P; Russo F; Sleeper MM; Knox VW; Fernandez S; Levanduski L; Hopwood J; De Leonibus E; Haskins M; Auricchio A
    Mol Ther; 2011 Mar; 19(3):461-9. PubMed ID: 21119624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial.
    Ferla R; Claudiani P; Savarese M; Kozarsky K; Parini R; Scarpa M; Donati MA; Sorge G; Hopwood JJ; Parenti G; Fecarotta S; Nigro V; Sivri HS; Van Der Ploeg A; Andria G; Brunetti-Pierri N; Auricchio A
    Hum Gene Ther; 2015 Mar; 26(3):145-52. PubMed ID: 25654180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectors.
    Ferla R; Alliegro M; Dell'Anno M; Nusco E; Cullen JM; Smith SN; Wolfsberg TG; O'Donnell P; Wang P; Nguyen AD; Chandler RJ; Chen Z; Burgess SM; Vite CH; Haskins ME; Venditti CP; Auricchio A
    Mol Ther Methods Clin Dev; 2021 Mar; 20():247-257. PubMed ID: 33473358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB.
    Drugs R D; 2005; 6(5):312-5. PubMed ID: 16128602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Capsid Proteins Impact Transduction Efficiency of Haploid Adeno-Associated Virus Vectors.
    Chai Z; Zhang X; Dobbins AL; Frost EA; Samulski RJ; Li C
    Viruses; 2019 Dec; 11(12):. PubMed ID: 31835440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Development and Characterization of Novel Adeno-Associated Viral Vectors for the Treatment of Lipoprotein Lipase Deficiency.
    Mehta N; Gilbert R; Chahal PS; Moreno MJ; Nassoury N; Coulombe N; Lytvyn V; Mercier M; Fatehi D; Lin W; Harvey EM; Zhang LH; Nazemi-Moghaddam N; Elahi SM; Ross CJD; Stanimirovic DB; Hayden MR
    Hum Gene Ther; 2023 Sep; 34(17-18):927-946. PubMed ID: 37597209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antiatherogenic effects of intravenous AAV8- and AAV2-mediated ApoA-IMilano gene transfer in hypercholesterolemic mice.
    Tian F; Wang L; Arias A; Yang M; Sharifi BG; Shah PK
    J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):66-75. PubMed ID: 24742767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain.
    Broekman ML; Comer LA; Hyman BT; Sena-Esteves M
    Neuroscience; 2006; 138(2):501-10. PubMed ID: 16414198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of clinical features and arylsulfatase B gene mutation in thirteen Chinese children with mucopolysaccharidosis type VI].
    Zheng J; Huang Y; Zhao X; Sheng H; Cheng J; Zhou Z; Li X; Mao X; Liu L
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):403-8. PubMed ID: 25190157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation.
    Kunieda T; Simonaro CM; Yoshida M; Ikadai H; Levan G; Desnick RJ; Schuchman EH
    Genomics; 1995 Oct; 29(3):582-7. PubMed ID: 8575749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B.
    Ferla R; Dell'Aquila F; Doria M; Ferraiuolo M; Noto A; Grazioli F; Ammendola V; Testa F; Melillo P; Iodice C; Risca G; Tedesco N; le Brun PR; Surace EM; Simonelli F; Galimberti S; Valsecchi MG; Marteau JB; Veron P; Colloca S; Auricchio A
    Mol Ther Methods Clin Dev; 2023 Mar; 28():396-411. PubMed ID: 36910588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
    Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
    Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders.
    Pañeda A; Vanrell L; Mauleon I; Crettaz JS; Berraondo P; Timmermans EJ; Beattie SG; Twisk J; van Deventer S; Prieto J; Fontanellas A; Rodriguez-Pena MS; Gonzalez-Aseguinolaza G
    Hum Gene Ther; 2009 Aug; 20(8):908-17. PubMed ID: 19419275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR
    Greig JA; Limberis MP; Bell P; Chen SJ; Calcedo R; Rader DJ; Wilson JM
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):39-50. PubMed ID: 28319449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in ARSB in MPS VI patients in India.
    Mathew J; Jagadeesh SM; Bhat M; Udhaya Kumar S; Thiyagarajan S; Srinivasan S
    Mol Genet Metab Rep; 2015 Sep; 4():53-61. PubMed ID: 26937411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.